ArticlePharmacoepidemiology and drug safety2026
Introduction to Concepts in Artificial Intelligence and Machine Learning for Pharmacoepidemiologists: Large Language Models.
Article in Pharmacoepidemiology and drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large language models (LLMs) represent a type of generative artificial intelligence (GenAI) that generate and interpret text, with some LLMs able to process multimodal content (e.g., images, audio, video), and can be deployed as part of agents to perform users' tasks. LLMs can perform natural language processing functions such as summarization, translation, and extraction giving them the potential to enhance and scale pharmacoepidemiological and real-world research by performing tasks such as literature review, data extraction, and medical writing. Despite the growing integration of GenAI tools into research workflows, their technical foundations and methodological implications remain unfamiliar to many pharmacoepidemiologists, who are often responsible for the reliability and accuracy of research that relies on these tools. This paper aims to inform pharmacoepidemiologists about the capabilities and limitations of LLMs to support responsible integration into the field of pharmacoepidemiology, providing an intuitive overview of how LLMs work, focusing on training and text generation, and reviews current and emerging applications in drug effectiveness and safety research and epidemiology. The article addresses challenges associated with LLM use in real-world evidence generation, including concerns regarding reproducibility, bias, hallucinations, plagiarism, data privacy, and the need for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.